Skip to main content
  • Home
  • Serum Institute of India
Institutional profile

Serum Institute of India

Serum Institute of India is one of the most important vaccine manufacturers in the world by volume. Its institutional role is especially important in low- and middle-income countries, where large-scale affordable vaccine supply is essential to immunization programs.

  • Highest 2026 tier: Tier II
  • Vaccine & Immunotherapy Developers
  • 1 ranking category

Overview

Serum Institute of India is one of the most important vaccine manufacturers in the world by volume. Its institutional role is especially important in low- and middle-income countries, where large-scale affordable vaccine supply is essential to immunization programs.

The WHO’s 2025 Global Vaccine Market Report identifies Serum Institute of India as the dominant manufacturer by volume, with roughly twice the volume of the next-largest manufacturer. It also notes that developing-country vaccine manufacturers provide a major share of global vaccine volume, especially for lower-income markets.

Serum Institute of India is included in 1 2026 ranking category. Its highest classification is Tier II. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.

Firm facts

Public identitySerum Institute of India
Founded1966
Institution typeVaccine & Immunotherapy Developers institution
HeadquartersPune, India
Primary focusVaccine & Immunotherapy Developers
Highest 2026 ranking tierTier II

Principal activities

The WHO’s 2025 Global Vaccine Market Report identifies Serum Institute of India as the dominant manufacturer by volume, with roughly twice the volume of the next-largest manufacturer. It also notes that developing-country vaccine manufacturers provide a major share of global vaccine volume, especially for lower-income markets.

Core capability

Vaccine & Immunotherapy Developers

Client relevance

Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.

Execution and verification

Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.

Sector and mandate coverage

Primary category

Vaccine & Immunotherapy Developers

Institutional context

Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.

Market position

Its volume leadership, global immunization role, and manufacturing capacity support its inclusion among established vaccine developers.

Serum Institute of India is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier II.

Competitive context

The relevant peer set varies by category, geography, client segment and mandate. Serum Institute of India should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.

Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.

Leadership and governance

Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.

Corporate and public information

The public-facing organization is identified here as Serum Institute of India. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.

Corporate and disclosure information
OrganizationSerum Institute of India
HeadquartersPune, India
Verification noteConfirm legal entity, licenses, offices and engagement terms directly before appointment or use.

Rankings and recognition

2026

Tier II

Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.

Related Economy analysis

Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:

Sources and data transparency

Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.

  1. Healthcare Ranking — Top 30 Vaccine & Immunotherapy Developers 2026 — 2026 inclusion and tier classification.
  2. The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
  3. The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
  4. The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.

First published: 29 August 2026

Last substantively reviewed: 29 August 2026

Profile scope: Vaccine & Immunotherapy Developers

This profile has been compiled from publicly available institutional and editorial sources. The profiled organization does not determine its inclusion, editorial characterization or ranking status. Corrections supported by authoritative documentation may be submitted to The Economy Wiki.